findmyKOL
Clinical trialNCT04706598Active, not recruitingPhase 1/PHASE2Interventional

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

SponsorFudan UniversityEnrollment25ImmunotherapyUrinary Bladder Neoplasms
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Xiang Wang, MD

    Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    Study Director
  • Xudong Yao, MD

    Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine

    Study Director
  • Yushan Liu, MD

    Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

    Study Director

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanghai General Hospital,shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Ninth People'S Hospital,shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Tenth People'S Hospital,shanghai Tong Ji University School of Medicine

    Shanghai, Shanghai Municipality, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Jun 2021
Primary completion
11 Jul 2024
Completion
31 Dec 2024
Last update posted
12 Jul 2024
Registered enrollment
25
Registry id
NCT04706598

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.